Alzamend Neuro's R&D Soars, Net Loss Triples Amid Reverse Splits

TL;DR

**ALZN is burning cash fast on R&D, and while they raised capital, the 'going concern' warning means this is a high-stakes bet on clinical trial success.**

AI Summary

Alzamend Neuro, Inc. (ALZN) reported a significant increase in net loss for the three months ended July 31, 2025, reaching $2,702,684, a substantial rise from $974,411 in the same period of 2024. This was primarily driven by a surge in research and development expenses, which escalated to $1,740,867 from $206,571 year-over-year, reflecting increased investment in its AL001 and ALZN002 drug candidates for Alzheimer's, bipolar disorder, major depressive disorder, and PTSD. General and administrative expenses also increased to $959,334 from $755,834. Despite these losses, the company improved its cash position, with cash increasing to $5,620,872 as of July 31, 2025, from $3,948,658 on April 30, 2025, largely due to $4,035,000 in net proceeds from preferred stock issuance. The company executed a one-for-nine reverse stock split on May 12, 2025, following a one-for-ten split on July 16, 2024, to manage its share structure. With an accumulated deficit of $61.2 million and continued operating losses, the company acknowledges substantial doubt about its ability to continue as a going concern without further capital raises.

Why It Matters

Alzamend Neuro's substantial increase in R&D spending, while driving a larger net loss, signals aggressive pursuit of its Alzheimer's and mental health drug candidates, AL001 and ALZN002. For investors, this indicates a high-risk, high-reward profile; success in clinical trials could lead to significant upside, but continued losses and the 'going concern' warning highlight the precarious financial position. Employees face uncertainty given the need for continuous capital raises, while potential patients and the broader market await breakthroughs in critical disease areas where effective treatments are scarce. The competitive landscape for Alzheimer's treatments is intense, and ALZN's ability to secure funding and advance its pipeline will determine its viability against larger pharmaceutical players.

Risk Assessment

Risk Level: high — The company explicitly states "These factors create substantial doubt about our ability to continue as a going concern" due to an accumulated deficit of $61.2 million and a net loss of $2.7 million for the three months ended July 31, 2025. Cash used in operating activities was $2.4 million for the same period, indicating a rapid cash burn rate relative to its cash balance of $5.6 million.

Analyst Insight

Investors should approach ALZN with extreme caution, recognizing it as a highly speculative investment. Monitor upcoming clinical trial results for AL001 and ALZN002 closely, as these will be critical catalysts. Any investment should be a small, diversified portion of a portfolio, acknowledging the significant risk of capital loss due to the ongoing 'going concern' issues and reliance on future financing.

Financial Highlights

debt To Equity

0.18

revenue

$0

operating Margin

-99.9%

total Assets

$ 6,326,751

total Debt

$ 983,311

net Income

$ -2,702,684

eps

$ -1.28

gross Margin

N/A

cash Position

$ 5,620,872

revenue Growth

N/A

Key Numbers

• $2.7M — Net Loss (Increased from $0.97M in Q3 2024, reflecting higher R&D.)
• $1.74M — Research and Development Expenses (Significantly up from $0.21M in Q3 2024, indicating increased pipeline investment.)
• $5.62M — Cash at End of Period (Increased from $3.95M at April 30, 2025, primarily from preferred stock issuance.)
• $61.24M — Accumulated Deficit (Grew from $58.54M, highlighting ongoing losses and capital needs.)
• $4.04M — Net Proceeds from Preferred Stock Issuance (Key financing activity for the three months ended July 31, 2025.)
• 1-for-9 — Second Reverse Stock Split Ratio (Effective May 12, 2025, impacting share structure.)
• $1.28 — Basic and Diluted Net Loss Per Share (Compared to $11.42 in Q3 2024, influenced by reverse stock splits and increased share count.)
• 3,139,861 — Common Shares Outstanding (As of September 10, 2025, significantly higher than 778,733 on April 30, 2025.)

Key Players & Entities

• Alzamend Neuro, Inc. (company) — registrant
• University of South Florida Research Foundation, Inc. (company) — licensor of AL001 and ALZN002
• SEC (regulator) — Securities and Exchange Commission
• NASDAQ Capital Market (market) — exchange where ALZN common stock is registered
• AL001 (product) — ionic cocrystal technology for Alzheimer's, BD, MDD, PTSD
• ALZN002 (product) — cell-based therapeutic vaccine for Alzheimer's
• $2,702,684 (dollar_amount) — net loss for three months ended July 31, 2025
• $1,740,867 (dollar_amount) — research and development expenses for three months ended July 31, 2025
• $5,620,872 (dollar_amount) — cash balance as of July 31, 2025
• $61,237,945 (dollar_amount) — accumulated deficit as of July 31, 2025

FAQ

Risk Factors

• Going Concern Uncertainty [high — financial]: The company has an accumulated deficit of $61.2 million and has incurred significant net losses, including $2.7 million for the three months ended July 31, 2025. Management acknowledges substantial doubt about its ability to continue as a going concern without further capital raises, indicating a high degree of financial risk.
• High R&D Spending [high — operational]: Research and development expenses surged to $1.74 million for the three months ended July 31, 2025, from $0.21 million in the prior year period. While this reflects investment in drug candidates, the significant increase strains financial resources and requires successful clinical outcomes.
• Dependence on Capital Raises [high — financial]: The company's ability to continue operations is contingent on its ability to secure additional financing. The recent $4.04 million net proceeds from preferred stock issuance highlights this reliance, and future capital needs remain a significant concern.
• Reverse Stock Splits [medium — operational]: Alzamend executed a one-for-nine reverse stock split on May 12, 2025, following a one-for-ten split in July 2024. These actions are often taken to meet exchange listing requirements or improve share price perception, but can signal underlying financial challenges.
• Drug Development Risks [high — regulatory]: The company is developing drug candidates for complex neurological conditions like Alzheimer's, bipolar disorder, and PTSD. These development pathways are inherently long, expensive, and carry a high risk of failure due to regulatory hurdles and clinical trial outcomes.

Industry Context

Alzamend Neuro operates in the highly competitive and capital-intensive biotechnology sector, focusing on neurological disorders. The industry is characterized by long development cycles, high failure rates in clinical trials, and significant regulatory oversight from bodies like the FDA. Success hinges on innovative drug discovery, robust clinical data, and substantial funding to navigate these challenges.

Regulatory Implications

As a clinical-stage biopharmaceutical company, Alzamend faces stringent regulatory requirements for drug approval. The success of its drug candidates (AL001 and ALZN002) is contingent upon successful clinical trials and FDA approval, which involves significant time, cost, and risk of failure. Any delays or setbacks in the regulatory process can severely impact the company's prospects.

What Investors Should Do

1. Monitor R&D spending and clinical trial progress closely.
2. Assess the company's cash burn rate and future financing needs.
3. Understand the implications of reverse stock splits.
4. Evaluate the competitive landscape and market potential for drug candidates.

Key Dates

• 2025-07-31: End of Third Quarter 2025 — Reported a net loss of $2.7 million, with R&D expenses significantly increasing to $1.74 million. Cash position improved to $5.62 million due to preferred stock issuance.
• 2025-05-12: One-for-Nine Reverse Stock Split — Executed to manage share structure, following a previous reverse split, impacting share count and per-share metrics.
• 2025-04-30: End of Second Quarter 2025 — Cash position was $3.95 million. Accumulated deficit stood at $58.5 million.
• 2024-07-31: End of Third Quarter 2024 — Reported a net loss of $0.97 million, with R&D expenses at $0.21 million. Basic and diluted EPS was -$11.42.
• 2024-07-16: One-for-Ten Reverse Stock Split — Previous reverse stock split aimed at adjusting the company's share structure.

Glossary

Accumulated deficit

The total net losses of a company since its inception that have not been offset by net income. (Indicates the company's historical unprofitability and its cumulative need for capital. Alzamend's deficit grew to $61.2 million.)

Going concern

The assumption that a company will continue to operate for the foreseeable future. If there is substantial doubt, it must be disclosed. (Alzamend acknowledges substantial doubt about its ability to continue as a going concern, highlighting significant financial risks.)

Research and development (R&D) expenses

Costs incurred by a company in the process of developing new products or services, or improving existing ones. (Alzamend's R&D expenses dramatically increased to $1.74 million, reflecting significant investment in its drug candidates.)

Reverse stock split

A corporate action to reduce the number of outstanding shares of stock, typically to increase the share price. (Alzamend has implemented multiple reverse stock splits (1-for-9 and 1-for-10) to manage its share structure.)

Preferred stock

A class of ownership in a corporation that has a higher claim on assets and earnings than common stock. (Alzamend raised $4.04 million in net proceeds from preferred stock issuance, a key source of recent funding.)

Basic and diluted net loss per common share

The net loss attributable to each outstanding share of common stock, considering potential dilution from convertible securities or options. (Alzamend reported a loss per share of $1.28 for the period, impacted by reverse stock splits and share count changes.)

Year-Over-Year Comparison

Compared to the three months ended July 31, 2024, Alzamend Neuro reported a substantial increase in net loss, rising from $0.97 million to $2.7 million. This widening loss was primarily driven by a near eight-fold increase in research and development expenses, which climbed to $1.74 million from $0.21 million, indicating a significant ramp-up in pipeline investment. General and administrative expenses also saw an increase. Despite the deteriorating operational performance, the company's cash position improved due to a preferred stock issuance, and the basic and diluted net loss per share decreased significantly from -$11.42 to -$1.28, largely due to reverse stock splits and an increased weighted average common shares outstanding.

Key Financial Figures

• $0.0001 — nge on which registered Common Stock, $0.0001 par value per share ALZN NASDAQ Capit
• $0 — uly 31, 2024, with an exercise price of $0.54, from its anti-dilutive securities a

Filing Documents

• u9325010q.htm (10-Q) — 628KB
• ex31_1.htm (EX-31.1) — 8KB
• ex31_2.htm (EX-31.2) — 8KB
• ex32_1.htm (EX-32.1) — 5KB
• 0001214659-25-013609.txt ( ) — 3253KB
• alzm-20250731.xsd (EX-101.SCH) — 31KB
• alzm-20250731_cal.xml (EX-101.CAL) — 27KB
• alzm-20250731_def.xml (EX-101.DEF) — 98KB
• alzm-20250731_lab.xml (EX-101.LAB) — 222KB
• alzm-20250731_pre.xml (EX-101.PRE) — 173KB
• u9325010q_htm.xml (XML) — 425KB

Financial Statements (unaudited)

Financial Statements (unaudited) 3 Condensed Balance Sheets 3 Condensed Statements of Operations 4 Condensed Statements of Stockholders' Equity 5 Condensed Statements of Cash Flows 7 Notes to Condensed Financial Statements 8 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 18 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 26 Item 4.

Controls and Procedures

Controls and Procedures 26 PART II. OTHER INFORMATION 28 Item 1.

Legal Proceedings

Legal Proceedings 28 Item 1A.

Risk Factors

Risk Factors 28 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 28 Item 3. Defaults Upon Senior Securities 28 Item 4. Mine Safety Disclosures 28 Item 5. Other Information 28 Item 6. Exhibits 28

– FINANCIAL INFORMATION

PART I – FINANCIAL INFORMATION

FINANCIAL STATEMENTS

ITEM 1. FINANCIAL STATEMENTS Alzamend Neuro, Inc. Condensed Balance Sheets July 31, 2025 April 30, 2025 ASSETS (Unaudited) (Audited) CURRENT ASSETS Cash $ 5,620,872 $ 3,948,658 Prepaid expenses and other current assets 307,958 228,719 TOTAL CURRENT ASSETS 5,928,830 4,177,377 Property and equipment, net 397,921 425,606 TOTAL ASSETS $ 6,326,751 $ 4,602,983 LIABILITIES AND STOCKHOLDERS' EQUITY CURRENT LIABILITIES Accounts payable and accrued liabilities $ 983,311 $ 634,761 TOTAL LIABILITIES, ALL CURRENT 983,311 634,761 COMMITMENTS AND CONTINGENCIES STOCKHOLDERS' EQUITY Series B Convertible Preferred Stock, $ 1,000 stated value per share, 6,000 designated; 1,535.24 and 2,100 issued and outstanding as of July 31, 2025 and April 30, 2025, respectively - - Series C Convertible Preferred Stock, $ 10,000 shares designated; nil 0 and 150.7176 issued and outstanding as of July 31, 2025 and April 30, 2025, respectively - - Common stock, $ 0.0001 par value: 300,000,000 shares authorized; 3,139,861 and 778,733 issued and outstanding as of July 31, 2025 and April 30, 2025, respectively 314 78 Additional paid-in capital 66,581,071 62,503,405 Accumulated deficit ( 61,237,945 ) ( 58,535,261 ) TOTAL STOCKHOLDERS' EQUITY 5,343,440 3,968,222 TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $ 6,326,751 $ 4,602,983 The accompanying notes are an integral part of these unaudited condensed financial statements. 3 Alzamend Neuro, Inc. Condensed Statements of Operations (Unaudited) For the Three Months Ended July 31, 2025 2024 OPERATING EXPENSES Research and development $ 1,740,867 $ 206,571 General and administrative 959,334 755,834 Total operating expenses 2,700,201 962,405 Loss from operations ( 2,700,201 ) ( 962,405 ) OTHER EXPENSE, NET Interest expense ( 2,483 ) ( 12,006 ) Total other expense, net ( 2,483 ) ( 12,006 ) NET LOSS $ ( 2,702,684 )

View Full Filing

View this 10-Q filing on SEC EDGAR